Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Conditions:   Corneal Edema;   Corneal Defect;   Anterior Chamber Inflammation;   Ocular Pain;   Corneal Staining;   Visual Outcome;   CME - Cystoid Macular Edema Interventions:   Drug: Dextenza 0.4Mg Ophthalmic Insert;   Drug: Prednisolone Phosphate 1%/Moxifloxacin 0.5%/Bromfenac 0.075% compound Sponsor:   Nicole Fram M.D. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials